Ariad Pharmaceuticals Inc fka ARIA

[biotech_researcher]

ARIA)

Massachusetts based Ariad Pharmaceuticals was riding pretty high until January of 2013, when its approved leukemia drug Ponatinib was found to cause life-threatening blood clots. The drug now carries a black box warning, and is back in clinical trials as Ariad tries to find an optimal dosage. Ponatinib may never be what it once was, but, perhaps more importantly, Ariad has two lung cancer drugs in development: Brigatinib, in Phase 3, and AP32788 in Phase 1 & 2. With its market cap of $1.93 billion and $278 million in cash, its $491 million in debt shouldn’t be enough to spoil the party.